Vast's first platform, Haven-1, is deliberately modest in scale but ambitious in both schedule and purpose. The station is designed as a roughly 15-ton autonomous outpost ...
Recently, JinkoSolar, a globally innovative photovoltaic enterprise, announced a strategic partnership with a renowned UK clean energy distributor, successfully securing a 56.89MW order for its ...
Sentiment among Europe’s solar buyers dropped to the lowest levels on record at the end of 2025, according to sun.store's ...
Until today, Haven-1 had a public launch date of mid-2026. However, as Haot explained in our interview, that launch date is ...
The proposed Coordinate-Aware Feature Excitation (CAFE) module and Position-Aware Upsampling (Pos-Up) module both adhere to ...
Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for ...
Families of four young Texas women killed when an inattentive truck driver hauling H-E-B merchandise rear-ended their vehicle ...
Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
The IMCAS test team for the reconfigurable flexible on-orbit manufacturing platform. Credit: IMCAS HELSINKI — A Chinese institute recently completed ground tests on what it describes as a ...
Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...
The CA01 'super module' has been installed at unit 1 of the Lufeng nuclear power plant in China's Guangdong province, the Shanghai Nuclear Engineering Research and Design Institute announced. (Image: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback